Oculis holding agOCS.US Overview

US StockHealthcare

(No presentation for OCS)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

OCS Overall Performance

OCS AI Analysis & Strategy

OCS Recent Performance

2.19%

Oculis holding ag

0.81%

Avg of Sector

-1.14%

S&P500

OCS PowerScanner

OCS Key Information

OCS Valuation Metrics

OCS Earnings Table

OCS Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.